© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Benefits of Lung Cancer Screening: A Conversation with Kim Sandler, MD
April 07, 2025
ACP 2025: Kim Sandler, MD, sat down with Patient Care to discuss the benefits of lung cancer screening, citing a 20% reduction in lung cancer mortality with annual screenings.
FDA Approves Gepotidacin for Treatment of Uncomplicated UTIs: Daily Dose
April 07, 2025
Your daily dose of the clinical news you may have missed.
Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial
April 04, 2025
Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.
Lung Cancer Screening: A Missed Opportunity for Early Detection
April 04, 2025
ACP 2025: Kim Sandler, MD, discussed the latest screening guidelines, real-world challenges in implementation, and the essential role of shared decision-making.
Universal Syphilis Screening in the ED Outperforms Targeted Approaches: Daily Dose
April 04, 2025
Your daily dose of the clinical news you may have missed.
Alopecia Management in Primary Care: Expert Insights from ACP 2025
April 03, 2025
William Lewis, MD, discussed the importance of photo-documentation, referral indicators, efficacy of various treatments, and other topics.
ACP: Invest in Rural Communities to Decrease Health Disparities, Improve Access to Care
April 03, 2025
In a new position paper, the ACP calls for policy action to address rural health disparities, improve access to care, and strengthen the rural health care workforce.
Responsive Parenting Intervention Curbs Childhood Obesity Risk: Daily Dose
April 03, 2025
Your daily dose of the clinical news you may have missed.
Osteoporosis Screening Misses Younger Postmenopausal Women: Daily Dose
April 02, 2025
Your daily dose of the clinical news you may have missed.
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study
April 01, 2025
Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.